

✓  
In the Claims

Please cancel without prejudice claims 2-7, 10-17, 21-23, 25-27, 29-34, 36, 37, 39, 42, 44, 46, 48 and 49.

Please amend the claims as follows:

A1 18. An expression vector comprising the isolated nucleic acid molecule of any of claims 1[-17], 8 or 9 operably linked to a promoter.

A2 20. An isolated polypeptide encoded by the isolated nucleic acid molecule of [any of] claim[s] 1 [-8].

A3 24. An isolated polypeptide which binds selectively a polypeptide encoded by the isolated nucleic acid molecule [any of] claim[s] 1 [-8].

A4 28. A method for diagnosing a disorder characterized by expression of a tumor associated nucleic acid molecule as claimed in claim 1, comprising:  
contacting a biological sample isolated from a subject with an agent that is specific for the tumor associated nucleic acid molecule, wherein the tumor associated nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, and  
determining the interaction between the agent and the tumor associated nucleic acid molecule as a determination of the disorder.

A5  
CONT'D  
Sub D3 40. A composition comprising:  
an antisense nucleic acid which binds to a tumor associated nucleic acid molecule as claimed in claim 1 which hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43,

AS  
conceded  
Sub  
23

and reduces the expression of the tumor associated nucleic acid, and  
a pharmaceutically acceptable carrier.

41. A kit for detecting the presence of the expression of a tumor associated polypeptide precursor as claimed in claim 1 comprising a first isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of SEQ ID NO:38, and a second isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of the complement of SEQ ID NO:38, wherein the contiguous segments are nonoverlapping.


43. A kit for detecting the presence of the expression of a tumor associated polypeptide precursor as claimed in claim 1 comprising a first isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of SEQ ID NO:43, and a second isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of the complement of SEQ ID NO:43, wherein the contiguous segments are nonoverlapping.

Al  
No

REMARKS

Please enter this Preliminary Amendment before calculating the fees.

Respectfully submitted,

  
John R. Van Amsterdam  
Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Tel. (617)720-3500

ATTY DOCKET NO. L0461/7047  
Date: February 16, 1999  
X02/16/99